Lab Rats series: A Bengaluru startup’s bid to drug the undruggable
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Bengaluru startup Peptris Technologies, founded in 2019, uses AI to speed up drug discovery for hard-to-treat diseases.
- ✓The firm recently secured ₹86 crore under the government’s RDI Fund.
- ✓CEO Venkat said, “The advantage with using a technology like the one that we have is that it is agnostic.”
Story at a Glance
- Category
- BUSINESS
- Reported By
- Livemint
- Reading Speed
- 5 Minute(s)
- Market Focus
- India Economy
These casual interactions eventually evolved into serious discussions on how technology and artificial intelligence (AI) could intersect with drug discovery, culminating in the establishment of an AI-driven drug discovery platform. The goal was to leverage AI to accelerate discovery timelines while targeting hard-to-treat diseases with significant unmet medical needs.
Founded in 2019, Peptris Technologies was incubated at the sprawling Centre for Cellular and Molecular Platforms (C-CAMP) campus in Bengaluru. Its proprietary AI platform accelerates the discovery of potential molecules ready for wet-lab testing and expands the scope of diseases and drug targets for which candidate molecules can be identified.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Livemint
Read the full, original unfiltered story directly on the publisher's portal.